Insider Selling: Nurix Therapeutics (NASDAQ:NRIX) Insider Sells 5,394 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 5,394 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $20.00, for a total value of $107,880.00. Following the completion of the transaction, the insider directly owned 115,005 shares in the company, valued at approximately $2,300,100. The trade was a 4.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Thursday, April 30th, Gwenn Hansen sold 3,214 shares of Nurix Therapeutics stock. The stock was sold at an average price of $16.65, for a total value of $53,513.10.

Nurix Therapeutics Stock Up 16.4%

NASDAQ:NRIX traded up $3.16 during midday trading on Thursday, reaching $22.46. The stock had a trading volume of 5,326,252 shares, compared to its average volume of 1,513,415. The firm has a fifty day simple moving average of $16.74 and a two-hundred day simple moving average of $16.96. Nurix Therapeutics, Inc. has a 12-month low of $8.19 and a 12-month high of $23.09. The stock has a market cap of $2.32 billion, a P/E ratio of -7.11 and a beta of 1.86.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Wednesday, April 8th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%.The firm had revenue of $6.25 million for the quarter, compared to analysts’ expectations of $14.25 million. On average, sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.88 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on NRIX shares. Jefferies Financial Group increased their price target on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, June 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating and set a $32.00 target price on shares of Nurix Therapeutics in a research report on Wednesday, June 10th. Needham & Company LLC reissued a “buy” rating and set a $34.00 target price on shares of Nurix Therapeutics in a research note on Monday, June 15th. Finally, Robert W. Baird lifted their price target on Nurix Therapeutics from $26.00 to $33.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Fourteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $32.20.

Institutional Trading of Nurix Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Nurix Therapeutics by 11.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,804 shares of the company’s stock worth $593,000 after buying an additional 5,286 shares during the period. Millennium Management LLC grew its holdings in shares of Nurix Therapeutics by 106.2% in the 1st quarter. Millennium Management LLC now owns 874,399 shares of the company’s stock worth $10,388,000 after acquiring an additional 450,262 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Nurix Therapeutics by 9.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 507,471 shares of the company’s stock worth $6,029,000 after acquiring an additional 44,002 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Nurix Therapeutics by 8.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 159,530 shares of the company’s stock valued at $1,895,000 after purchasing an additional 12,817 shares in the last quarter. Finally, Creative Planning purchased a new position in Nurix Therapeutics in the 2nd quarter valued at approximately $187,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.